The multiple faces of Behçet's disease and its aetiological factors

Journal of the European Academy of Dermatology and Venereology

Volumn 15, Issue 2, 2001, Pages 126-136

  Onder M ^a   Gurer M A ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Aetiological factors; Beh et's disease; Clinical features

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANESTHETIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CHLORHEXIDINE; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GLYCEROL; HLA B27 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; LIDOCAINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; STEROID; SUCRALFATE; TACROLIMUS; TETRACYCLINE; THALIDOMIDE; TRIAMCINOLONE; UNINDEXED DRUG;

ANEURYSM; ARTHRITIS; ARTICLE; BACTERIOLOGY; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EYE DISEASE; FEMALE; GENITAL ULCER; HEREDITY; HUMAN; IMMUNOLOGY; MALE; MORTALITY; MOUTH ULCER; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; SKIN MANIFESTATION; SYSTEMIC DISEASE; THROMBOSIS; TREATMENT PLANNING; VASCULAR DISEASE; VASCULITIS; VIROLOGY;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; BEHCET SYNDROME; CHRONIC DISEASE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 0034832752     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2001.00251.x     Document Type: Article

References (101)

1. Ueber rezidiverende aphtoese, durch ein virus verur sachte Geschwuere am mund am Auge und an den Genitalien
2. Description of Behçet's syndrome in the Hippocratic third book of endemic diseases
3. Behçet disease Behçet syndrome
4. Familial Behçe's disease
5. Behçet's disease. Report of 41 cases and review of the literature
6. Summary of international symposium on Behçet's disease
7. Behçet's syndrome in 32 patients in Yorkshire
8. A nation wide survey of Behçet's disease in Japan
9. The prevalence of Behçet's syndrome in a rural area in northern Turkey
10. Epidemiology of Behçet's syndrome in Turkey
11. Clinical manifestations of Behçet's disease: An analysis of 2147 patients
12. Criteria for diagnosis of Behçet's disease
13. Behçet's disease and complex aphthosis
14. Behçet's disease: An enigmatic vasculitis
15. Behçet's disease
16. Behçet's disease
17. Behçet's disease
18. Mucocutaneous criteria for the diagnosis of Behçet's disease: An analysis of clinicopathologic data from multiple international centers
19. Comparison of histopathologic and clinical evaluations of pathergy test in Behçet's disease
20. The ocular manifestations of Behçet's disease
21. Papilledema in Behçet's syndrome
22. Color doppler imaging in uveitis
23. Why Behçet's disease should be accepted as a seronegative arthritis
24. Large artery involvement in Behçet's disease
25. Arterial thrombosis leading to intestinal infarction in a Behçet's disease associated with protein C deficiency
26. Cardiovascular manifestations of Behçet's disease
27. Vascular involvement in Behçet's disease: 8 year audit
28. Pulmonary manifestations in Behçet's syndrome
29. IgA nephropathy in patients with Behçet's syndrome: Case report and review of literature
30. Intestinal involvement in Behçet's disease: Review of 136 surgical cases in the Japanese literature
31. Behçet's disease and the nervous system
32. Long term MR follow up of cerebral lesions in neuro-Behçet's disease
33. Hearing loss in Behçet's disease
34. A psychosomatic investigation of Behçet's disease
35. Cutaneous vasculitis in Behçet's disease. A clinical and histopathological study of 20 patients
36. A new kind of skin lesion in Behçet's disease: Extragenital ulcerations
37. Adamantiades-Behçet's disease. Serum IL-8 is a more reliable marker for disease activity than c-reactive protein and erythrocyte sedimentation rate
38. Behçet's disease: Report of twenty-five patients from United States with prominent mucocutaneous involvement
39. The relationship of HLA-B and DR phenotypes to Behçet's syndrome. Recurrent oral ulceration and the class of immune complexes
40. HLA antigens in Behçet's disease: A reappraisal by a comparative study of Turkish and British patients
41. Close association of HLA BW 51 with Behçet's disease
42. The association of HLA-B5 antigen with specific manifestations of Behçet's disease
43. HLA antigen and linkage disequilibrium patterns in Turkish Behçet's patients
44. Skin hypersensitivity to streptococcal antigens and the introduction of systemic symptoms by the antigens in Behçet's disease - A multicenter study
45. Behçet's disease and streptococcal infection
46. Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test
47. Immunological studies on aphthous ulcer and erythema nodosum like eruptions in Behçet's disease
48. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease
49. The isolation of a virus as the cause of Behçet's disease
50. Detection of RNA complementary herpes simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulceration
51. Natural killer cell activity, interferon gamma and antibodies to herpes viruses in patients with Behçet's disease
52. Detection of HSV 1 DNA in patients with Behçet's syndrome in patients with recurrent oral ulcers by the polymerase chain reaction
53. Search for human herpes virus 6, human cytomegalovirus and varicella zoster virus DNA in recurrent aphthous stomatitis tissue
54. Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease
55. Possible association between Behçet's syndrome and chronic hepatitis C virus infection
56. Behçet's disease and HCV infection
57. Association between the 65 kilodalton heat shock protein, streptococcus sangius and the corresponding antibodies in Behçet's syndrome
58. T cell epitope expression of mycobacterial and homologous human 65 kd heat shock protein peptides in short term cell lines from patients with Behçet's disease
59. Recognition of B cell epitopes of the 65 kd HSP in Behçet's disease
60. Immunopathology of Behçet's disease
61. Neutrophil adhesion to endothelial cells and factors affecting adhesions in patients with Behçet's disease
62. Serum levels of IL-8 in patients with Behçet's disease
63. Cutaneous fibrinolytic potential tPA dependent is reduced in Behçet's disease
64. Coagulation and fibrinolytic activity in Behçet's disease
65. Defective fibrinolysis in Behçet's syndrome. Significance and possible mechanisms
66. Monocyte activity in Behçet's disease
67. TNF, soluble IL-2R and soluble CD 8 in Behçet's disease
68. Cytokines in Behçet's disease
69. Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood Chinese patients with neuro Behçet's syndrome
70. Analysis of the profile of CD4+ cells in Behçet's disease
71. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity
72. Behçet's hastaliginda humoral immunite
73. Alterations of the cellular immunity in Behçet's disease
74. Circulating immune complexes in active Behçet's disease
75. Abnormal B cell function in patients with Behçet's disease
76. Phenotipic characteristics of B cells in Behçet's disease: Increased activity in B cell subsets
77. Natural cellular cytotoxicity in Behçet's disease
78. Arachidonic acid metabolites in Behçet's disease
79. Antibodies to endothelial cells in patients with Behçet's disease
80. Enhanced superoxide generation and decreased superoxide scavenging activity of peripheral blood leukocytes in Behçet's disease
81. Auto antibodies against oxidatively modified low density lipoprotein in patients with Behçet's disease
82. Impaired prostacyclin synthesis by vessel walls in Behçet's disease
83. Anticardiolipin antibodies in Adamantiades-Behçet's disease
84. Protein S deficiency and antibodies to Protein S in patients with Behçet's disease
85. Circulating thrombomodulin as a clue of endothelial damage
86. LPa lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease
87. Ocular Immunopathology of Behçet's disease
88. Endothelin 1 expression in serum and bronchoalveolar lavage from patients with active Behçet's disease
89. Behçet's syndrome. How should we treat it?
90. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet's disease
91. Azothioprine in Behçet's syndrome
92. Efficacy of cyclosporine on mucocutaneous manifestations of Behçet's disease
93. Thalidomide in the treatment of mucocutaneous lesions of the Behçet's syndrome
94. Arachidonic acid metabolites and colchicine in Behçet's disease
95. Interferon alfa-2a in the treatment of Behçet's disease
96. Treatment of Adamantiades-Behçet's disease with systemic interferon alfa
97. Long term effects of interferon alpha 2 a treatment of Behçet's disease
98. FK 506 treatment of noninfectious uveitis
99. Aneurysms after arterial puncture in Behçet's disease
100. Other forms of vasculitis and pseudovasculitis
101. The management of Behçet's syndrome. How are we doing?